[go: up one dir, main page]

AR008864A1 - DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA - Google Patents

DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA

Info

Publication number
AR008864A1
AR008864A1 ARP970104503A ARP970104503A AR008864A1 AR 008864 A1 AR008864 A1 AR 008864A1 AR P970104503 A ARP970104503 A AR P970104503A AR P970104503 A ARP970104503 A AR P970104503A AR 008864 A1 AR008864 A1 AR 008864A1
Authority
AR
Argentina
Prior art keywords
alkyl
preparation
compounds
compositions
amino
Prior art date
Application number
ARP970104503A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR008864A1 publication Critical patent/AR008864A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Compuestos derivados de diamino-1,3,5-triazina sustituida que tienen la formula (1), las sales de adicion farmacéuticamente aceptables de los mismos ya las formas estereoquímicamente isoméricas de los mismos donde R1 y R2 están cada unoindepen dientemente seleccionados de hidrogeno, hidroxi, amino, alquiloC1-C6 opcionalmente sustituido; alquiloxi C1-C6; alquilcarbonilo C1-C6; alquiloxicarbonil C1-C6 Ar1 mono o di (alquilo C1-C6) amino; aminocarbonilomono o di (alquilo C1-C6);dihid ro -2(3H)-furanona; o R1 y R2 tomados conjuntamente pueden formar un anillo pirrolidinilo, piperidinilo, morfolinilo,ácido o mono o di (alquilo C1-C6) amino alquilideno C1-C4; R3 es hidrogeno. Ar1 alquilcarbonilo C1-C6, alquilo C1-C6, alquiloxi C1-C6-carbonilo, alquilo C1-C6substituido con alquiloxicarbonilo C1-C6; y R4, R5, R6, R7 y R8 están cada uno independientemente seleccionados de hidrogeno, halo, alquilo C1-C6, alquiloxiC1-C6, ciano, aminocarbonilo, nitro, amino, trialometiloo trialometiloxi; L es alquilo C1-C10 opcionalmente sustituido; alquenilo C3-C10; alquinilo C3-C10 ycicloalquilo C3-C7; Art1 es fenilo opcionalmente sustituido, para la manufactura de un medicamento para el tratamiento de individuos que suf rendeinfeccion causada por HIV (Virus de Inmunodeficiencia Humana). Además se refiere a nuevos compuestos que constituyen un subgrupo de los compuestos deformula (I), a su procedimiento de preparacion, a las composiciones que las comprenden, alprocedimiento de prepracion de dichas composiciones, al uso dedichos compuestos para la manufactur de un medicamento para el tratamiento de individuos que sufren de infeccion causada por HIV (Virus de InmunodeficienciaHumana) y la combinacion dedicho compuesto con un compuesto anti-retroviral y un producto que los contiene.
ARP970104503A 1996-10-01 1997-09-30 DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA AR008864A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2726096P 1996-10-01 1996-10-01

Publications (1)

Publication Number Publication Date
AR008864A1 true AR008864A1 (es) 2000-02-23

Family

ID=21836641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104503A AR008864A1 (es) 1996-10-01 1997-09-30 DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA

Country Status (34)

Country Link
US (4) US6380194B1 (es)
EP (1) EP0834507B1 (es)
JP (1) JP4127882B2 (es)
KR (1) KR100478846B1 (es)
CN (1) CN1083438C (es)
AP (1) AP914A (es)
AR (1) AR008864A1 (es)
AT (1) ATE267179T1 (es)
AU (1) AU740809B2 (es)
BR (1) BR9704937A (es)
CA (1) CA2216486A1 (es)
CZ (1) CZ297333B6 (es)
DE (1) DE69729153T2 (es)
DK (1) DK0834507T3 (es)
EE (1) EE03826B1 (es)
ES (1) ES2221679T3 (es)
HK (1) HK1009676A1 (es)
HR (1) HRP970526B1 (es)
HU (1) HU225270B1 (es)
ID (1) ID19599A (es)
IL (1) IL121849A (es)
MY (1) MY123803A (es)
NO (1) NO311614B1 (es)
NZ (1) NZ328854A (es)
OA (1) OA10620A (es)
PL (1) PL190155B1 (es)
PT (1) PT834507E (es)
RU (1) RU2186774C2 (es)
SG (1) SG53075A1 (es)
SI (1) SI0834507T1 (es)
SK (1) SK285241B6 (es)
TR (1) TR199701070A2 (es)
TW (1) TW411335B (es)
ZA (1) ZA978766B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
EA004501B1 (ru) * 1998-11-10 2004-04-29 Янссен Фармацевтика Н.В. Производные 2,4-дизамещенного триазина
PL204427B1 (pl) 1998-11-10 2010-01-29 Janssen Pharmaceutica Nv Hamująca replikację wirusa HIV pochodna pirymidyny, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AP1639A (en) * 1999-09-24 2006-07-24 Janssen Pharmaceutica Nv Pharmaceutical compositions of antiviral compounds and processes for preparation.
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
ES2335265T3 (es) * 1999-12-28 2010-03-24 Pharmacopeia, Inc. Inhibidores de citoquina, especialmente de tnf-alfa.
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
CA2451125A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
WO2003037869A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
NZ531853A (en) 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
EP1509515A4 (en) 2002-05-16 2006-07-05 Cytovia Inc SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE
WO2003096982A2 (en) * 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ATE402152T1 (de) * 2003-02-07 2008-08-15 Janssen Pharmaceutica Nv Hiv-inhibierende1,2,4-triazine
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2006015985A1 (en) 2004-08-10 2006-02-16 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazin-6-one derivatives
AU2005279615A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. 2,4,6-triamino-s-triazine-based compounds which bind to the tail (Fc) portion of immunoglobulins and their use
MX2007003798A (es) 2004-09-30 2007-04-23 Tibotec Pharm Ltd Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih.
AU2005288866B2 (en) 2004-09-30 2012-07-26 Janssen Sciences Ireland Uc HIV inhibiting 5-substituted pyrimidines
JP5008567B2 (ja) 2004-09-30 2012-08-22 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５−ヘテロシクリルピリミジン
ES2508766T3 (es) 2004-10-29 2014-10-16 Janssen R&D Ireland Derivados de pirimidina bicíclicos que inhiben el VIH
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
EP2114901B1 (en) 2006-12-29 2014-04-09 Janssen R&D Ireland Hiv inhibiting 6-substituted pyrimidines
JP5283633B2 (ja) * 2006-12-29 2013-09-04 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５，６−置換ピリミジン
PT2152676E (pt) * 2007-04-30 2013-06-25 Prometic Biosciences Inc Derivados de triazina, composições contendo tais derivados, e métodos de tratamento do cancro e de doenças autoimunes usando tais derivados
PT2268635E (pt) 2008-04-21 2015-10-06 Taigen Biotechnology Co Ltd Compostos heterocíclicos
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
US9058223B2 (en) * 2011-04-22 2015-06-16 Microsoft Technology Licensing Llc Parallel entropy encoding on GPU
PL2912024T3 (pl) * 2012-10-24 2017-01-31 Basf Se Chwastobójcze azyny
CN106458937A (zh) * 2014-04-11 2017-02-22 巴斯夫欧洲公司 作为除草剂的二氨基三嗪衍生物
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
CN105837525B (zh) * 2016-03-25 2019-05-28 浙江工业大学 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2309663A (en) * 1943-01-26 Process fok preparing substituted
DE226474C (es)
US2817814A (en) 1953-08-13 1957-12-24 Gen Electric Corona detection probe
US2817614A (en) * 1953-10-26 1957-12-24 Monsanto Chemicals Internally plasticized melamine resins and laminates made therewith
GB771327A (en) 1953-10-26 1957-03-27 Monsanto Chemicals Production of heat hardenable melamine-formaldehyde condensation products
JPS4927592B1 (es) 1970-05-13 1974-07-18
GB1390235A (en) 1971-08-07 1975-04-09 Kakenyaku Kako Kk 2-amino-4,6substituted-s triazines and methods for their preparation
DE3724379A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Verfahren zur herstellung feinteiliger magnetischer hexaferritpigmente
AU2599992A (en) * 1991-11-12 1993-06-15 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CN1142817A (zh) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater

Also Published As

Publication number Publication date
MX9707511A (es) 1998-06-30
IL121849A0 (en) 1998-02-22
TW411335B (en) 2000-11-11
HRP970526B1 (en) 2002-10-31
HU225270B1 (en) 2006-08-28
JP4127882B2 (ja) 2008-07-30
CZ297333B6 (cs) 2006-11-15
SI0834507T1 (en) 2004-10-31
IL121849A (en) 2001-08-26
OA10620A (en) 2002-09-03
NO311614B1 (no) 2001-12-17
ZA978766B (en) 1999-03-30
EP0834507B1 (en) 2004-05-19
NO974368D0 (no) 1997-09-22
RU2186774C2 (ru) 2002-08-10
EE9700253A (et) 1998-04-15
EP0834507A1 (en) 1998-04-08
US7449575B2 (en) 2008-11-11
US6858609B2 (en) 2005-02-22
MY123803A (en) 2006-06-30
CN1180698A (zh) 1998-05-06
AP9701109A0 (en) 1997-10-31
DE69729153T2 (de) 2005-01-27
US6962916B2 (en) 2005-11-08
HUP9701596A2 (hu) 1999-06-28
ES2221679T3 (es) 2005-01-01
HRP970526A2 (en) 1998-10-31
PL190155B1 (pl) 2005-11-30
DE69729153D1 (de) 2004-06-24
NZ328854A (en) 2000-10-27
CZ299397A3 (cs) 1998-11-11
ID19599A (id) 1998-07-23
CA2216486A1 (en) 1998-04-01
AU3926697A (en) 1998-04-09
NO974368L (no) 1998-04-02
SK131997A3 (en) 1999-06-11
EE03826B1 (et) 2002-08-15
US20030199473A1 (en) 2003-10-23
CN1083438C (zh) 2002-04-24
AP914A (en) 2000-12-18
KR19980032428A (ko) 1998-07-25
KR100478846B1 (ko) 2006-06-13
PT834507E (pt) 2004-10-29
AU740809B2 (en) 2001-11-15
HU9701596D0 (en) 1997-11-28
ATE267179T1 (de) 2004-06-15
US20020147181A1 (en) 2002-10-10
SG53075A1 (en) 1998-09-28
JPH10114759A (ja) 1998-05-06
HK1009676A1 (en) 1999-06-04
DK0834507T3 (da) 2004-09-06
BR9704937A (pt) 2000-06-06
SK285241B6 (sk) 2006-09-07
HUP9701596A3 (en) 2000-04-28
PL322369A1 (en) 1998-04-14
US6380194B1 (en) 2002-04-30
TR199701070A2 (xx) 1998-04-21
US20060189614A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
AR008864A1 (es) DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA
EA200000990A1 (ru) Вич-ингибирующие производные пиримидина
AR018169A1 (es) Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret
AR014785A1 (es) Derivados de pirimidina, uso de dichos derivados para la preparacion de medicamentos para el tratamiento de hiv,composicion farmaceutica que los comprende,procedimiento para prepararla, procedimiento para preparar dichos derivados, e intermediarios utiles en la preparacion de dichos derivados.
ES2178037T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
PA8552901A1 (es) Derivados de pirimidina inhibidores de vih
ECSP066361A (es) Derivados de piperazina
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
UY28578A1 (es) Derivados de amida
MX9204454A (es) Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene.
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
MXPA03005464A (es) Agentes antivirales.
CR7069A (es) Derivados de pirazol para el tratamiento de vih
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
BR0315958A (pt) Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
NO930143L (no) Piperidinforbindelser, deres fremstilling og bruk
AR049405A1 (es) Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo
DK0527081T3 (da) Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
AR021137A1 (es) Derivados de triazina 2,4-disustituida, uso de los mismos para preparar medicamentos, composiciones farmacéuticas que los comprenden, procedimiento para prepararlas, y procedimiento para preparar dichos derivados.

Legal Events

Date Code Title Description
FG Grant, registration